BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bydureon exenatide once weekly regulatory update

FDA accepted an NDA resubmission from Amylin for Type II diabetes candidate once-weekly Bydureon exenatide. The agency designated the NDA a Class 2 resubmission, with a PDUFA date of...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >